<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Achilles' operating expenses trend in Q3 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 03:13am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Achilles Therapeutics's operating expenses for Q3 2024 are not currently available. However, the latest available data is from the second quarter ended June 30, 2024, where the company reported total operating expenses of $17,799. This total includes research and development expenses of $13,635 and general and administrative expenses of $4,164. Comparing this to the previous quarter's operating expenses of $18,092 in the second quarter of 2023, there is a slight decrease in operating expenses for the latest quarter. This indicates a potential cost-saving effort or a shift in strategy that may have led to reduced expenditures. However, without specific Q3 2024 data, a definitive trend cannot be determined.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:D,comeFrom:"AInvestShareLink",events:[],answerSource:i}],fetch:{},error:j,state:{sharePreviewModule:{loadJgySuccess:g,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:i,cache_builder:a,reply_action:"Answer",execute_mode:u,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Achilles' operating expenses trend in Q3 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Achilles' operating expenses trend in Q3 2024?\",\"user_id\":\"dp13526821\",\"user_name\":\"\",\"trace_id\":\"9f0b94b4-3ff5-400a-8f1f-4e0526ba3d24\",\"session_id\":\"9f0b94b4-3ff5-400a-8f1f-4e0526ba3d24\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:E,title:F,summary:G,full_summary:"– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology – – Provided interim Phase I\u002FIIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment – – Cash position of $95.1 million supports operations through 2025 – LONDON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and recent business highlights. “During the second quarter we shared interim Phase I\u002FIIa data from our ongoing CHIRON and THETIS TIL-based cNeT clinical trials and established an important research collaboration with Arcturus Therapeutics to explore the use of clonal neoantigens in second-generation personalized mRNA cancer vaccines”, said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics. “Our insights into the factors that drive durable engraftment and immune evasion led us to add an additional cohort in the CHIRON and THETIS trials to evaluate cNeT persistence and clinical activity in patients with enhanced host conditioning (EHC). These findings, along with the cancer vaccine research collaboration, continue to illustrate the potential value of our platform, including the unparalleled capability of PELEUS to select tumor targets with the highest potential for immune system recognition in a variety of modalities including TIL, neoantigen vaccines, ADCs, and TCR-T therapies. Our financial position remains strong with more than $95 million in cash, which we expect to support operations through 2025, including the completion of the ongoing Phase I\u002FIIa trials and the Arcturus collabora",url:H,image_url:a,video_url:a,publish_time:I,search_extra_info:{search_burial_info:{id:v,uid:J,ab:{scene_id:K,layer_exp:[{layer_id:L,exp_id:M}]}}},simhash:"207b4b47aed1fd61",msg_id:v}}],answer_chain_name:N,agent_mode:O,native_answer:a,come_from:a,text_answer:D,trace_id:e,cost:14384,event_names:a,question:d,fallback_type:P,input_type:Q,fall_back_reason:{fall_back_type:P,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:e,first_return_cost:2275,cache_type:"no_cache",question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:w,remote_svc:i,slots:[],answer_type:u,user_id:r,skill_name:x},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:r,question:d,source:i,raw_question:d,version:"3.4.1",action_name:x,nlu:{entity:[{type:R,value:"ACHL.O",market:S}]},output_time:w,deep_research:c,deep_thinking:c,agent_mode:O},extra:{}},{answer_path:k,section:{id:l,info_texts:["Thinking"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:k,section:{id:l,info_texts:["Querying Stock: ACHL Operating Expenses in Q3 2024"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:T},logs:[],extra:{action:"Querying Stock",action_input:"ACHL Operating Expenses in Q3 2024",thought:"The user seeks to analyze Achilles Therapeutics' operating expenses in Q3 2024. I should focus on its Q3 2024 operating expenses data. I will use FinQuery for the data mentioned above."}},{answer_path:f,section:{id:y,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Searching Web: Achilles Therapeutics Q3 2024 Operating Expenses"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:T},logs:[],extra:{action:"Searching Web",action_input:"Achilles Therapeutics Q3 2024 Operating Expenses",thought:"I am unable to obtain Achilles Therapeutics' Q3 2024 operating expenses by FinQuery, now I will try again using Search."}},{answer_path:f,section:{id:y,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:y,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Generating Answer"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:z,info_texts:[],show_type:A,voice_txt:"A",text_answer:U,rich_text:U,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:2000,info_texts:[],show_type:A,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:H,image_url:a,video_url:a,title:F,summary:G,index:E,publish_time:I,search_id:v,search_uid:J,search_ab:{scene_id:K,layer_exp:[{layer_id:L,exp_id:M}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:z,info_texts:[],show_type:A,voice_txt:". This",text_answer:V,rich_text:V,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:f,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"ACHL",market_id:S,name:W,domain:R},pos:g,section_id:z,txt:W,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Completed"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"0823e47644fefe2ced7177afbb374c0e",item_type:h,item_name:n,rec_info:X}},{display_text:o,query_text:o,trace_info:{item_id:"66b784e83e80413be9768cc9b8c5d6c9",item_type:h,item_name:o,rec_info:Y}},{display_text:p,query_text:p,trace_info:{item_id:"1519d9307c1e109e0f480f8fb575f015",item_type:h,item_name:p,rec_info:Z}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:g,type:"1",display2:c,url:a}},request_config:[{source_type:_,related_name:$}],puuid:B,tag:a,category:"custom",uuid:aa}],global:{urp_static_data:[{name:$,value:{status_code:g,columns:[{type:q,index_name:ab,key:ab},{type:q,index_name:ac,key:ac},{type:q,index_name:ad,key:ad},{type:q,index_name:ae,key:ae},{type:q,index_name:af,key:af}],datas:[{send_text:n,item_type:h,rec_info:X,display_text:n,rec_reason:a},{send_text:o,item_type:h,rec_info:Y,display_text:o,rec_reason:a},{send_text:p,item_type:h,rec_info:Z,display_text:p,rec_reason:a}],dataSize:_,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ag,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:t,"min-height":"100%",position:ah,height:t},isMaterial:c,id:ag,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:g,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:C,componentUuid:aa,script:[{name:ai,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:C,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:C},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:t,position:ah,height:t},isMaterial:b,_id:19,id:ai,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:aj,voice_txt:a,tracking_info:{},uuid:B},order:{is_auto:c,render_for:aj,chart_type:"command",puuid:B}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:x,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:u,answer_chain_name:N},is_deep_research:c,deep_thinking:c,create_time:1746731649314},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:j,docsData:[],quoteData:j},tplType:"question"},events:ak,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:ak,client_ip:a,question:d,user_id:r,user_name:a,trace_id:e,session_id:e,source:i,input_type:Q}}],userId:r,userName:a,startTime:w,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:j,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:g,traceTableData:j,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-achilles-operating-expenses-trend-in-q3-2024-b07f15\u002F",config:{_app:{basePath:al,assetsPath:al,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"How did Achilles' operating expenses trend in Q3 2024?","9f0b94b4-3ff5-400a-8f1f-4e0526ba3d24","other\u002FopenAnswer",0,"llm_generated","ths_ainvest_lite_web",null,"progress\u002Fsearching_for",1000,"searching_for","What was Achilles' operating expense ratio in Q3 2024?","What was the impact of Achilles' operating expenses on its Q3 2024 earnings?","How did analysts' expectations of Achilles' operating expenses align with the actual Q3 2024 results?","STR","dp13526821","signal","auto","agent","6425a0878aed04ff_4",1746731634930,"inspect stocks",999,2001,"rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Achilles Therapeutics's operating expenses for Q3 2024 are not currently available. However, the latest available data is from the second quarter ended June 30, 2024, where the company reported total operating expenses of $17,799. This total includes research and development expenses of $13,635 and general and administrative expenses of $4,164. Comparing this to the previous quarter's operating expenses of $18,092 in the second quarter of 2023, there is a slight decrease in operating expenses for the latest quarter. This indicates a potential cost-saving effort or a shift in strategy that may have led to reduced expenditures. However, without specific Q3 2024 data, a definitive trend cannot be determined.",2,"Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates","Dollars, unless otherwise stated)     Three Months Ended Six Months Ended   June 30, June 30,   2024 2023 2024 2023  OPERATING EXPENSES:   Research and development $ 13,635 $ 13,774 $ 23,775 $ 27,642   General and administrative 4,164 4,318 8,323 9,003   Total operating expenses 17,799 18,092 32,098...","https:\u002F\u002Fwww.streetinsider.com\u002FGlobe+Newswire\u002FAchilles+Therapeutics+Reports+Second+Quarter+2024+Financial+Results+and+Recent+Business+Updates\u002F23596935.html","2024-08-14","6425a0878aed04ff","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","186","thinking","Achilles Therapeutics's operating expenses for Q3 2024 are not currently available. However, the latest available data is from the second quarter ended June 30, 2024, where the company reported total operating expenses of $17,799[^2]",". This total includes research and development expenses of $13,635 and general and administrative expenses of $4,164. Comparing this to the previous quarter's operating expenses of $18,092 in the second quarter of 2023, there is a slight decrease in operating expenses for the latest quarter. This indicates a potential cost-saving effort or a shift in strategy that may have led to reduced expenditures. However, without specific Q3 2024 data, a definitive trend cannot be determined.","Achilles","2+679_496_21_554+0+0+9f0b94b4-3ff5-400a-8f1f-4e0526ba3d24+0823e47644fefe2ced7177afbb374c0e+llm_generated+aimeTagAnalysis+0+0.03390657529234886+1","2+679_496_21_554+0+0+9f0b94b4-3ff5-400a-8f1f-4e0526ba3d24+66b784e83e80413be9768cc9b8c5d6c9+llm_generated+aimeTagAnalysis+0+0.011430773884057999+2","2+679_496_21_554+0+0+9f0b94b4-3ff5-400a-8f1f-4e0526ba3d24+1519d9307c1e109e0f480f8fb575f015+llm_generated+aimeTagAnalysis+0+0.0087904566898942+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>